Herpes Zoster Clinical Trial
Official title:
A Phase II Clinical Trial of Vaccination of Stem Cell Donors With Zostavax to Reduce the Incidence of Herpes Zoster in Transplant Recipients - A Pilot Study
The purpose of this study is to determine whether vaccination of stem cell donors with
Zostavax can reduce the rate of Herpes Zoster reactivations in transplant recipients.
The clinical hypotheses is: 1) that Zostavax given to stem cell donors will induce protective
VZV specific T cell proliferation in allogeneic stem cell transplant recipients that can be
transferred to recipients; 2) and that donor vaccination with Zostavax is safe for transplant
recipients as measured by viral load measurement by polymerase chain reaction assay (PCR) at
the time of stem cell donation.
Infection is a major cause of morbidity and death among haemopoietic stem cell
transplantation patients (HSCTs). Beyond the initial post-transplant (BMT) phase of
neutropenia, the most common infections are cytomegalovirus (CMV) and fungal infections.
Another common infection for which BMT patients are at increased risk is varicella-zoster
virus (VZV) (both primary varicella and herpes zoster). VZV infection is controlled by
specific T cell responses that are impaired post stem cell transplant.
Heat inactivated VZV vaccine has been shown to more than halve the incidence of herpes zoster
in adult BMT patients undergoing autologous transplantation. Clinical protection was
correlated with in vitro CD4 T-cell proliferation in response to varicella-zoster virus.
Being a live vaccine, attenuated VZV and (herpes zoster (HZ) vaccines are contraindicated
within 24 months after allogeneic HSCT. However, priming of donor T-cells with herpes zoster
vaccine may be a feasible alternative. One possible complication is the transfer of live
virus from vaccinated donors to immunocompromised stem cell transplant recipients.
Normal donors donating for HLA matched siblings will be vaccinated with the Varivax vaccine
prior to donation. Stem cell products will be assessed at the time of donation for evidence
of VZV by PCR and for response to vaccination by T cell proliferation. Transfer of VZV
proliferative responses in transplant recipients will be assessed by VZV specific T cell
proliferation at 3, 6, 9 and 12 months post transplantation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03120364 -
Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
|
Phase 3 | |
| Completed |
NCT01165203 -
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
|
Phase 2 | |
| Recruiting |
NCT06088745 -
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
|
Phase 3 | |
| Completed |
NCT01385566 -
A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
|
Phase 1 | |
| Completed |
NCT01137669 -
ZOSTAVAX® in Renal Transplant Patients
|
Phase 1 | |
| Completed |
NCT01911065 -
T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
|
Phase 4 | |
| Completed |
NCT00550745 -
ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
|
Phase 4 | |
| Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
| Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
| Completed |
NCT00231816 -
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
|
Phase 3 | |
| Completed |
NCT02852876 -
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
|
Phase 1 | |
| Completed |
NCT05082688 -
Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)
|
Phase 2 | |
| Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
| Active, not recruiting |
NCT04091451 -
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles
|
Phase 3 | |
| Completed |
NCT02519855 -
Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
|
Phase 3 | |
| Completed |
NCT04523246 -
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
|
Early Phase 1 | |
| Completed |
NCT05047770 -
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
|
Phase 3 | |
| Completed |
NCT03314103 -
Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age
|
Phase 3 | |
| Completed |
NCT01527370 -
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
|
Phase 3 | |
| Completed |
NCT01954251 -
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
|
Phase 3 |